Due to the large amount of detailed data in the Natsal-3 dataset, including information from survey participants which is of a highly-sensitive nature, great care is needed when preparing a publically-available dataset in order to avoid potential breach of confidentiality. At the time of writing, final preparations are being made to archive the \>1,600 variables in the Natsal-3 dataset in June 2015 at which point these data will be publicly-available from the UK Data Archive ([www.data-archive.ac.uk](http://www.data-archive.ac.uk)). In the meantime, researchers can contact the Natsal team to request secure access to the Natsal-3 dataset, including those variables used for the analyses presented in this paper. The contact details to do so are those of the paper\'s corresponding author.

Introduction {#sec005}
============

It is well-established that male circumcision reduces HIV acquisition.\[[@pone.0130396.ref001]--[@pone.0130396.ref003]\] A meta-analysis concluded that male circumcision is also associated with a lower risk of infection with herpes simplex virus type 2, chancroid and syphilis.\[[@pone.0130396.ref004]\] However, the effect of male circumcision on non-ulcerative sexually transmitted infections (STIs) remains unclear.

Human Papillomavirus (HPV) is highly prevalent.\[[@pone.0130396.ref005]\] Persistent infection with 'high-risk' types (HR-HPV) is essential for the development of cervical cancer in women, and anal cancer in both men and women. HR-HPV has also been associated with penile cancers in men.\[[@pone.0130396.ref006]\] 'Possible HR-HPV' types are those with no clear evidence of carcinogenicity in humans, and types HPV-6 and HPV-11 are responsible for around 85% of genital warts.\[[@pone.0130396.ref007]\] A meta-analysis using detection of HPV DNA and/or genital warts (by self-report/clinical examination) as outcomes found that circumcision was strongly protective against HPV DNA detection (summary odds ratio (OR) 0.57; 95% Confidence Interval (CI) 0.45--0.71), but with substantial between-study heterogeneity, which may partly reflect the fact that most of the data were from convenience samples with relatively small sample sizes, while circumcision did not afford protection against genital warts.\[[@pone.0130396.ref008]\]

*Chlamydia trachomatis* and *Mycoplasma genitalium* are bacterial STIs possibly associated with upper reproductive tract infection in women. A randomised trial of circumcision to prevent acquisition of HIV in Kenya found Chlamydia infection was reduced in the intervention arm, but this lacked significance (incidence rate ratio 0.87, 95% CI 0.65--1.16).\[[@pone.0130396.ref009]\] However, in the same trial, circumcision almost halved the odds of detecting *M*. *genitalium* (OR 0.54; 95% CI 0.29--0.99), after controlling for behavioural risks.\[[@pone.0130396.ref009]\] A similar trial in South Africa demonstrated a decrease in prevalence of *C*. *trachomatis* in circumcised participants (adjusted OR 0.56; 95% CI 0.32--1.00).\[[@pone.0130396.ref010]\] However, few other studies have investigated the association between circumcision and these pathogens.

Our study examined the relationship between male circumcision and reporting previous STI diagnoses or detecting HPV, *C*. *trachomatis* and *M*. *genitalium* in urine among men in the British general population.

Materials and Methods {#sec006}
=====================

The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) was a stratified probability sample survey of 15,162 men and women (6293 men) aged 16--74 years in Britain, who were interviewed during 2010--2012. The overall response rate was 57.7%. Participants were interviewed using computer-assisted face-to-face and self-interviews (CASI). The CASI included questions about male circumcision, sexual behaviour and history of STI diagnoses. Further methodological details have been described elsewhere.\[[@pone.0130396.ref011],[@pone.0130396.ref012]\]

After the interview, a sample of participants aged 16--44 years who reported at least one lifetime sexual partner were invited to provide urine for STI testing.\[[@pone.0130396.ref005],[@pone.0130396.ref011]\] Samples were tested for HPV, *C*. *trachomatis* and *M*. *genitalium*. STI test results were available from 1,850 men. HPV types were classified as high-risk, possible high-risk or HPV-6/11 using the IARC Monograph Working Group classification \[[@pone.0130396.ref013]\] (see [Table 2](#pone.0130396.t002){ref-type="table"}). Details of the urine collection methods and testing procedures are published elsewhere.\[[@pone.0130396.ref005]\] Briefly, detection of *C*. *trachomatis* used the Aptima Combo 2 assay (Hologic Gen-Probe) as the initial screen and all positive or equivocal results were confirmed with the Aptima monospecific assay. An in-house Luminex-based genotyping assay was used to detect HPV types.\[[@pone.0130396.ref014]\] *M*. *genitalium* detection used an in-house Real-Time PCR assay which targets the adhesin protein (MgPa) gene, \[[@pone.0130396.ref015]\] with positive or equivocal results confirmed using a Genprobe Mycoplasma test. \[[@pone.0130396.ref016]\]

Stata (version 12.1) was used for all statistical analyses accounting for the stratification, clustering, and weighting of the sample, which was broadly representative of the British population.\[[@pone.0130396.ref011]\] Analyses were additionally weighted for unequal urine selection probabilities and differential urine sample response.\[[@pone.0130396.ref011]\] The denominator was limited to men aged 16--44 years reporting one or more lifetime partner. Prevalence estimates of self-reported circumcision with 95% confidence intervals (CIs) are presented. Associations between circumcision and demographic and behavioural variables were examined using logistic regression to calculate odds ratios (ORs). Crude and age-adjusted ORs are presented. To examine the association between circumcision and self-reported STI diagnoses or biological outcomes multivariable analysis was used to calculate ORs adjusted for age, ethnicity, same-sex experience and either number of lifetime partners (for STI diagnosis outcomes) or number of partners without a condom in the past year (for biological outcomes) (adjusted OR \[AOR\]).

All participants were given an information leaflet to read prior to participating in the survey and had the opportunity to discuss this with the interviewer. Verbal informed consent was obtained for participation in the interview and interviewers had to confirm that respondents had read the information leaflet in the computer programme before commencing the interview. Participants gave written informed consent for anonymised testing of urine samples, without the return of results, the ethical rationale for which has been previously described.\[[@pone.0130396.ref014]\] The Natsal-3 study, including the consent procedures, was approved by the Oxfordshire Research Ethics Committee A (reference: 09/H0604/27). All participants provided their own consent to participate, however for 16--17 year olds living at home, a parent/guardian provided additional verbal assent for participation. At the time of writing, the Natsal-3 data are being prepared for archiving with the UK Data Archive in June 2015, but before then, researchers may contact the Natsal-3 team to seek advance access to the corresponding data, and are directed to the Natsal website for further information ([www.natsal.ac.uk](http://www.natsal.ac.uk)).

Results {#sec007}
=======

The prevalence of reported circumcision in sexually-experienced men aged 16--44 resident in Britain was 17.4% (95% CI 16.0--19.0). Prevalence increased with age, from 13.2% (95% CI 11.3--15.5) among men aged 16--24 to 18.4% (95% CI 15.5--21.6) among men aged 35--44 ([Table 1](#pone.0130396.t001){ref-type="table"}). Prevalence of male circumcision varied greatly according to ethnicity and religion, with men from ethnic minority backgrounds being significantly more likely to report being circumcised than men of White ethnicity. In unadjusted analyses, the odds of circumcision were 45.01 (95%CI 24.26--83.51) times higher in Muslim men than in those of no religious background. This association remained after adjusting for age. There were no associations between circumcision and the key sexual behaviours studied.

10.1371/journal.pone.0130396.t001

###### Variations in the prevalence of circumcision by key sociodemographic factors and sexual behaviours reported by sexually--experienced^1^ men aged 16--44 years in Britain's third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

![](pone.0130396.t001){#pone.0130396.t001g}

                                                                                                             Circumcised   OR             (95%CI)     p-value          Age-adjusted OR   (95%CI)                       Denom. (unwt, wt)[^1^](#t001fn001){ref-type="table-fn"}   
  ---------------------------------------------------------------------------------------------------------- ------------- -------------- ----------- ---------------- ----------------- ------------ ---------------- --------------------------------------------------------- ----------------
  **All**                                                                                                                                                                                                                                                                        
  ***Sociodemographics***                                                                                                                                                                                                                                                         
  **Age (years)**                                                                                                                                                      p = 0.0005                                                                                                
  16--24                                                                                                     13.20%        (11.3--15.5)   1           \-                                                                                                                         *1343*, *979*
  25--34                                                                                                     19.60%        (17.5--22.0)   1.6         (1.26--2.03)                                                                                                               *1425*, *1273*
  35--44                                                                                                     18.40%        (15.5--21.6)   1.47        (1.12--1.94)                                                                                                               *777*, *1374*
  **Relationship status**                                                                                                                                              p = 0.0324                                      p = 0.2641                                                
  Living with partner                                                                                        19.10%        (17.0--21.5)   1           \-                                 1            \-                                                                         *1603*, *2130*
  Steady relationship, not cohabiting                                                                        13.80%        (11.0--17.2)   0.68        (0.50--0.91)                       0.75         (0.54--1.05)                                                               *769*, *586*
  No steady relationship, previously cohabited                                                               15.60%        (11.7--20.6)   0.78        (0.54--1.13)                       0.8          (0.55--1.15)                                                               *338*, *272*
  No steady relationship, never cohabited                                                                    15.50%        (12.8--18.7)   0.78        (0.59--1.02)                       0.88         (0.64--1.21)                                                               *821*, *627*
  **Academic qualifications** [^**2**^](#t001fn002){ref-type="table-fn"}                                                                                               p = 0.0012                                      p = 0.0003                                                
  No academic qualifications                                                                                 16.60%        (12.0--22.6)   1           \-                                 1            \-                                                                         *316*, *347*
  Academic qualifications typically gained at age 16                                                         13.60%        (11.5--16.1)   0.79        (0.51--1.21)                       0.81         (0.53--1.25)                                                               *1216*, *1248*
  Studying for/attained further academic qualifications                                                      19.80%        (17.7--22.1)   1.24        (0.83--1.86)                       1.35         (0.90--2.04)                                                               *1815*, *1860*
  **Ethnic group**                                                                                                                                                     p\<0.0001                                       p\<0.0001                                                 
  White                                                                                                      12.00%        (10.8--13.4)   1           \-                                 1            \-                                                                         *3106*, *3093*
  Mixed                                                                                                      37.40%        (26.1--50.3)   4.38        (2.58--7.45)                       4.63         (2.72--7.88)                                                               *88*, *82*
  Asian/Asian British                                                                                        48.80%        (40.0--57.6)   6.97        (4.80--10.13)                      6.83         (4.67--9.97)                                                               *175*, *254*
  Black/Black British                                                                                        64.40%        (53.9--73.8)   13.26       (8.38--20.99)                      13.27        (8.37--21.02)                                                              *123*, *137*
  Other                                                                                                      29.80%        (17.0--46.8)   3.10        (1.50--6.43)                       3.15         (1.50--6.64)                                                               *47*, *53*
  **Religion**                                                                                                                                                         p\<0.0001                                       p\<0.0001                                                 
  None                                                                                                       13.60%        (12.0--15.4)   1           \-                                 1            \-                                                                         *2288*, *2249*
  Christian                                                                                                  16.20%        (13.6--19.3)   1.23        (0.96--1.58)                       1.2          (0.93--1.55)                                                               *1022*, *1091*
  Muslim                                                                                                     87.60%        (79.5--92.8)   45.01       (24.26--83.51)                     45.44        (24.62--83.86)                                                             *119*, *149*
  Hindu                                                                                                      3.90%         (1.2--11.7)    0.26        (0.08--0.83)                       0.24         (0.07--0.79)                                                               *45*, *69*
  Other                                                                                                      21.50%        (13.3--32.9)   1.74        (0.96--3.16)                       1.8          (0.98--3.27)                                                               *66*, *63*
  ***Sexual behaviours***                                                                                                                                                                                                                                                         
  **Number of sexual partners** [^**3**^](#t001fn003){ref-type="table-fn"} **over the lifetime**                                          p = 0.256                                      p = 0.1224                                                                              
  1                                                                                                          21.00%        (16.8--25.9)   1           \-                                 1            \-                                                                         *483*, *490*
  2                                                                                                          20.50%        (15.1--27.0)   0.97        (0.62--1.53)                       0.99         (0.63--1.56)                                                               *306*, *303*
  3--4                                                                                                       17.40%        (13.9--21.6)   0.8         (0.55--1.15)                       0.79         (0.55--1.14)                                                               *532*, *528*
  5--9                                                                                                       16.00%        (13.1--19.2)   0.72        (0.50--1.02)                       0.68         (0.48--0.97)                                                               *865*, *900*
  10+                                                                                                        16.40%        (14.3--18.7)   0.74        (0.53--1.02)                       0.69         (0.49--0.96)                                                               *1316*, *1361*
  **Same sex experience, ever** [^**4**^](#t001fn004){ref-type="table-fn"}                                                                                             p = 0.8434                                      p = 0.8289                                                
  No                                                                                                         17.40%        (15.9--19.0)   1           \-                                 1            \-                                                                         *3343*, *3436*
  Yes                                                                                                        18.00%        (12.7--25.0)   1.04        (0.68--1.60)                       1.05         (0.68--1.61)                                                               *202*, *189*
  **Number of sexual partners** [^**3**^](#t001fn003){ref-type="table-fn"} **, past year**                                                            p = 0.723                                       p = 0.7831                                                                 
  0                                                                                                          17.80%        (12.2--25.3)   1           \-                                 1            \-                                                                         *189*, *172*
  1                                                                                                          17.70%        (15.8--19.7)   0.99        (0.62--1.58)                       0.98         (0.61--1.56)                                                               *2294*, *2581*
  2                                                                                                          14.50%        (11.0--18.8)   0.78        (0.46--1.35)                       0.84         (0.49--1.47)                                                               *421*, *355*
  3--4                                                                                                       18.20%        (13.7--23.7)   1.03        (0.59--1.79)                       1.1          (0.63--1.93)                                                               *354*, *287*
  5+                                                                                                         17.80%        (12.9--24.1)   1           (0.55--1.81)                       1.1          (0.60--2.01)                                                               *251*, *193*
  **Number of sexual partners** [^**3**^](#t001fn003){ref-type="table-fn"} **without a condom, past year**                 p = 0.6247                                  p = 0.9503                                                                                                
  0                                                                                                          16.50%        (13.6--20.0)   1           \-                                 1            \-                                                                         *859*, *781*
  1                                                                                                          17.80%        (15.8--19.9)   1.09        (0.83--1.43)                       1.03         (0.78--1.35)                                                               *2104*, *2372*
  2+                                                                                                         15.80%        (12.4--20.0)   0.95        (0.65--1.38)                       0.98         (0.67--1.41)                                                               *513*, *410*

1 Unweighted, weighted denominators: all 16--44 year old men reporting at least one lifetime partner by the time of their interview for Natsal-3

2 Participants aged ≥17 years

3 Includes both opposite and same-sex partners

4 Same-sex experience involving genital contact

Circumcision was not associated with reporting previous diagnosis/es of any STI, or specifically chlamydia or genital warts in 16--44 year old men ([Table 2](#pone.0130396.t002){ref-type="table"}). Results were similar in 16--74 year old men (data not shown). In unadjusted analyses, any HPV type was less likely to be detected in circumcised men as were HR-HPV and possible HR-HPV types (but not HPV types 6 and 11; [Table 2](#pone.0130396.t002){ref-type="table"}). Circumcised men were also less likely to have *C*. *trachomatis*, but not *M*. *genitalium* detected ([Table 2](#pone.0130396.t002){ref-type="table"}). After adjusting for key demographic and behavioural variables ([Table 2](#pone.0130396.t002){ref-type="table"}), circumcised men were still less likely to have any HPV-type detected in their urine when compared with uncircumcised men (AOR 0.26, 95% CI 0.13--0.50). An association also remained for both HR-HPV (AOR 0.14, 95% CI 0.05--0.40) and possible HR-HPV (AOR 0.24, 95% CI 0.06--0.94) and for *C*. *trachomatis* (AOR 0.09, 95% CI 0.01--0.77). Unadjusted and adjusted ORs for the association between circumcision and *M*. *genitalium* differed substantially due to confounding by ethnicity.

10.1371/journal.pone.0130396.t002

###### Variations in the reported diagnosis of, and detection of, current infection, of key STIs among sexually-experienced men aged 16--44 years in Britain's third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

![](pone.0130396.t002){#pone.0130396.t002g}

                                                                     Circumcised men   Uncircumcised men                                                       
  ------------------------------------------------------------------ ----------------- ------------------- ------- -------------- ------ -------------- ------ --------------
  ***Reported diagnosis of*:**                                                                                                                                 
  *Denom*. *(unwt*, *wt)* [^*2*^](#t002fn002){ref-type="table-fn"}   *561*, *627*      *2969*, *2980*                                                          
  Any STI [^3^](#t002fn003){ref-type="table-fn"}                     13.7%             (10.8--17.2)        13.9%   (12.4--15.5)   0.98   (0.73--1.32)   1.05   (0.75--1.48)
  Chlamydia infection                                                6.5%              (4.8--8.8)          6.2%    (5.3--7.2)     1.06   (0.73--1.52)   1.23   (0.81--1.86)
  Genital warts                                                      3.5%              (2.2--5.6)          3.9%    (3.1--4.9)     0.88   (0.51--1.51)   1.05   (0.60--1.86)
  ***Current infection with*:**                                                                                                                                
  *Denom*. *(unwt*, *wt)* [^*4*^](#t002fn004){ref-type="table-fn"}   *284*, *403*      *1566*, *1821*                                                          
  HPV (any)                                                          6.4%              (4.0--10.2)         18.6%   (16.1--21.3)   0.30   (0.18--0.51)   0.26   (0.13--0.50)
  HR-HPV [^5^](#t002fn005){ref-type="table-fn"}                      2.3%              (1.0--4.9)          9.8%    (7.8--12.2)    0.21   (0.09--0.49)   0.14   (0.05--0.40)
  Possible HR-HPV [^6^](#t002fn006){ref-type="table-fn"}             0.6%              (0.2--2.0)          2.4%    (1.6--3.7)     0.25   (0.07--0.86)   0.24   (0.06--0.94)
  HPV-6/11                                                           0.7%              (0.2--2.5)          1.5%    (0.8--2.7)     0.48   (0.11--2.00)   0.58   (0.16--2.10)
  *Chlamydia trachomatis*                                            0.1%              (0.0--0.7)          1.3%    (0.9--1.9)     0.08   (0.01--0.59)   0.09   (0.01--0.77)
  *Mycoplasma genitalium*                                            1.9%              (0.7--5.1)          1.0%    (0.6--1.7)     1.90   (0.62--5.87)   0.61   (0.18--2.09)

1 ORs adjusted for age, ethnicity, same sex experience and number of partners in lifetime (for diagnosis outcomes) or number of partners without a condom in the past year (for biological outcomes)

2 Unweighted, weighted denominators: all 16--44 year old men reporting at least one lifetime partner by the time of their interview for Natsal-3

3 Defined as chlamydia, gonorrhoea, genital warts, syphilis, trichomonas, herpes, NSU/NGU, epididymo-orchitis, public lice/crabs or hepatitis

4 Unweighted, weighted denominators: 16--44 year old men with one or more lifetime partner who provided a urine sample

5 Positive for type(s) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68

6 Positive for type(s) 26, 53, 66, 70, 73 and/or 82

Discussion {#sec008}
==========

Findings from this large British population-based survey show that male circumcision is strongly associated with lower detection of any HPV and HR-HPV in urine, even after adjusting for key demographic and behavioural variables. However, circumcision was not associated with self-reported previous STI diagnosis/es in this population.

The strengths of this study are that the initial Natsal-3 sample size is large, and probability sampling gives data representative of the British general population.\[[@pone.0130396.ref011]\] In contrast, studies included in the meta-analysis of the association between HPV and genital warts and circumcision were generally convenience samples with relatively small sample sizes.\[[@pone.0130396.ref008]\] In addition to using self-reports of STI diagnosis/es, which may be subject to reporting bias (despite using CASI to collect these data \[[@pone.0130396.ref011]\]), Natsal-3 used biological markers of STI, which have greater reliability.\[[@pone.0130396.ref017]\] However, as the population prevalence of some of the STIs considered was low (specifically HPV-6/11, *C*. *trachomatis* and *M*. *genitalium*),\[[@pone.0130396.ref005]\] statistical power was too low to detect modest differences in prevalence. Thus, the observed strong association between circumcision and lower detection of Chlamydia should be interpreted with caution since the 95%CIs around this are wide. It is also necessary to consider the method of sample collection. Urine tests for *C*. *trachomatis* and *M*. *genitalium* are regarded as the 'gold standard' in men, but urine is considered a suboptimum specimen for detection of HPV. Hernandez *et al* assessed HPV prevalence at different sites and found that it was highest in the penile shaft (52% at this site) compared to just 10% in urine,\[[@pone.0130396.ref018]\] suggesting that HPV prevalence may be underestimated in our study. Another study found no difference in prevalence of HR-HPV in urethral swabs when comparing swabs taken before and after circumcision.\[[@pone.0130396.ref019]\] Although detection bias remains a possible explanation for our findings if the presence of the foreskin means that urine may collect HPV coming from other sites (e.g. the glans/corona,\[[@pone.0130396.ref018],[@pone.0130396.ref020],[@pone.0130396.ref021]\] where prevalence is higher), in addition to the urethra. However, a systematic review and meta-analysis, which included data collected from a variety of anatomical sites, found results similar to our study and a stronger effect of circumcision at sites more proximal to the foreskin (urethra and glans/corona)\[[@pone.0130396.ref008]\] suggesting that the results presented here may not solely be due to differential detection.

The lack of association between male circumcision and self-reported previous STI diagnoses is in keeping with Natsal-2 findings,\[[@pone.0130396.ref022]\] and the meta-analysis of the association between circumcision and HPV,\[[@pone.0130396.ref008]\] which reported significantly lower odds of any HPV type (at any anatomical site) in circumcised men compared to uncircumcised men but no association with genital warts. Our data suggest an association between circumcision and lower odds of detection of *C*. *trachomatis*, consistent with some,\[[@pone.0130396.ref010]\] but not all other studies.\[[@pone.0130396.ref009]\] However, we did not find an association with reported diagnosis of Chlamydia. We are unable to compare our findings for HPV-6/11 or *M*. *genitalium* to the findings of other studies due to insufficient statistical power.

Data from a large national probability survey have shown that male circumcision is associated with lower odds of detecting oncogenic HPV types. Reduced prevalence of oncogenic HPV types among men may result in reduced transmission to sexual partners, with the consequent effect of reduced risk of cervical cancer. Castellasgue *et al*. observed that monogamous women whose partners had reported six or more sexual partners and were circumcised were at lower risk of cervical cancer than monogamous women whose partners were uncircumcised.\[[@pone.0130396.ref023]\] Currently the World Health Organisation advocates male circumcision for HIV prevention;\[[@pone.0130396.ref024]\] reduction in HPV acquisition would add to the overall health benefit resulting from the scale-up of male circumcision in countries with high prevalence of HIV. In such settings this reduction could be important due to the higher incidence of cervical cancer, particularly among HIV positive women, as well as other HPV related cancers in both men and women than in higher income countries,\[[@pone.0130396.ref025]\] and the low or absent HPV vaccination coverage. This present study shows that male circumcision is associated with lower odds of detection of HR-HPV types, meaning it may convey a long-term public health benefit. Future research should be directed towards determining whether male circumcision might contribute to reducing rates of cervical, penile, anal and oral cancers.
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